Detection of HIV vaccine-induced cell-mediated immunity in HIV-seronegative clinical trial participants using an optimized and validated enzyme-linked immunospot assay

Journal of Acquired Immune Deficiency Syndromes

Volumn 45, Issue 1, 2007, Pages 20-27

  Dubey, Sheri ^a   Clair, James ^a   Fu, Tong Ming ^a   Guan, Liming ^a   Long, Romnie ^a   Mogg, Robin ^a   Anderson, Kiersten ^a   Collins, Kelly B ^a   Gaunt, Christine ^a   Fernandez, V Rose ^a   Zhu, Lan ^a   Kierstead, Lisa ^a   Thaler, Scott ^a   Gupta, Swati B ^a   Straus, Walter ^a   Mehrotra, Devan ^a   Tobery, Timothy W ^a,b   Casimiro, Danilo R ^a   Shiver, John W ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b PROCTER AND GAMBLE COMPANY   (United States)

Author keywords

ELISPOT; HIV 1; Interferon ; Interferon enzyme linked immunospot assay; Peptides; Vaccine

Indexed keywords

ADENOVIRUS VECTOR; GAG PROTEIN; GAMMA INTERFERON; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; PLACEBO;

ARTICLE; CELLULAR IMMUNITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DNA VECTOR; DRUG EFFICACY; ENZYME LINKED IMMUNOSPOT ASSAY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; PRIORITY JOURNAL; TREATMENT OUTCOME;

AIDS VACCINES; CLINICAL TRIALS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FALSE POSITIVE REACTIONS; HIV ANTIGENS; HIV INFECTIONS; HIV SERONEGATIVITY; HIV-1; HUMANS; INTERFERON TYPE II; LEUKOCYTES, MONONUCLEAR; PEPTIDES; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 34247635041     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3180377b5b     Document Type: Article

References (35)

1. Barresinoussi F, Chermann JC, Rey F, et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune-deficiency syndrome (AIDS). Science. 1983;220:868-871.
2. Gallo RC, Sarin PS, Gelmann EP, et al. Isolation of human T-cell leukemia-virus in acquired immune-deficiency syndrome (AIDS). Science. 1983;220:865-867.
3. Jin X, Bauer DE, Tuttleton SE, et al. Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques. J Exp Med. 1999;189:991-998.
4. Borrow P, Lewicki H, Hahn BH, et al. Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human-immunodeficiency-virus type-1 infection. J Virol. 1994;68:6103-6110.
5. Koup RA, Safrit JT, Cao YZ, et al. Temporal association of cellular immune-responses with the initial control of viremia in primary human-immunodeficiency-virus type-1 syndrome. J Virol. 1994;68:4650-4655.
6. Schmitz JE, Kuroda MJ, Santra S, et al. Control of viremia in simian immunodeficiency virus infection by CD8(+) lymphocytes. Science. 1999;283:857-860.
7. Shiver JW, Fu TM, Chen L, et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature. 2002;415:331-335.
8. Shiver JW, Emini EA. Recent advances in the development of HIV-1 vaccines using replication-incompetent adenovirus vectors. Annu Rev Med. 2004;55:355-372.
9. Letvin NL. Progress toward an HIV vaccine. Annu Rev Med. 2005;56:213-223.
10. Lalvani A, Brookes R, Hambleton S, et al. Rapid effector function in CD8(+) memory T cells. J Exp Med. 1997;186:859-865.
11. Schmittel A, Keilholz U, Scheibenbogen C. Evaluation of the interferon-gamma ELISPOT-assay for quantification of peptide specific T lymphocytes from peripheral blood. J Immunol Methods. 1997;210:167-174.
12. Sun Y, Iglesias E, Samri A, et al. A systematic comparison of methods to measure HIV-1 specific CD8 T cells. J Immunol Methods. 2003;272:23-34.
13. Mashishi T, Gray CM. The ELISPOT assay: an easily transferable method for measuring cellular responses and identifying T cell epitopes. Clin Chem Lab Med. 2002;40:903-910.
14. Kreher CR, Dittrich MT, Guerkov R, et al. CD4(+) and CD8(+) cells in cryopreserved human PBMC maintain full functionality in cytokine ELISPOT assays. J Immunol Methods. 2003;278:79-93.
15. Russell ND, Hudgens MG, Ha R, et al. Moving to human immunodeficiency virus type 1 vaccine efficacy trials: defining T cell responses as potential correlates of immunity. J Infect Dis. 2003;187:226-242.
16. Kierstead LS, Dubey SA, Meyer BE, et al. Enhanced rates and magnitude of immune responses detected against an HIV vaccine: effect of using an optimized process for isolating PBMC. AIDS Res Hum Retroviruses. 2007;23:86-92.
17. Lathey JL. Preliminary steps toward validating a clinical bioassay - a case study of the ELISpot assay. Biopharm International - The Applied Technologies of Biopharmaceutical Development. 2003;16:42-50.
18. Janetzki S, Cox JH, Oden N, et al. Standardization and validation issues of the ELISPOT assay. In: Kalyuzhny A, ed. Handbook of ELISPOT: Methods and Protocols. Humana Press, Totowa, NJ; 2005:51-86.
19. Mwau M, McMichael AJ, Hanke T. Design and validation of an enzyme-linked immunospot assay for use in clinical trials of candidate HIV vaccines. AIDS Res Hum Retroviruses. 2002;18:611-618.
20. Hudgens MG, Self SG, Chiu YL, et al. Statistical considerations for the design and analysis of the ELISpot assay in HIV-1 vaccine trials. J Immunol Methods. 2004;288:19-34.
21. Czerkinsky C, Andersson G, Ekre HP, et al. Reverse ELISpot assay for clonal analysis of cytokine production. 1. Enumeration of gamma-interferon- secreting cells. J Immunol Methods. 1988;110:29-36.
22. Coplan PM, Gupta SB, Dubey SA, et al. Cross-reactivity of anti-HIV-1 T cell immune responses among the major HIV-1 clades in HIV-1-positive individuals from 4 continents. J Infect Dis. 2005;191:1427-1434.
23. Fu TM, Dubey SA, Mehrotra D, et al. Evaluation of cellular immune responses in subjects chronically infected with HIV-1. AIDS Res Hum Retroviruses. 2007;23:67-76.
24. Maecker HT, Dunn HS, Suni MA, et al. Use of overlapping peptide mixtures as antigens for cytokine flow cytometry. J Immunol Methods. 2001;255:27-40.
25. Draenert R, Altfeld M, Brander C, et al. Comparison of overlapping peptide sets for detection of antiviral CD8 and CD4 T cell responses. J Immunol Methods. 2003;275:19-29.
26. Kiecker F, Streitz M, Ay B, et al. Analysis of antigen-specific T-cell responses with synthetic peptides - what kind of peptide for which purpose? Hum Immunol. 2004;65:523-536.
27. Vieira GF, Chies JAB. Immunodominant viral peptides as determinants of cross-reactivity in the immune system - can we develop wide spectrum viral vaccines? Med Hypotheses. 2005;65:873-879.
28. Smith JG, Liu X, Kaufhold RM, et al. Development and validation of a gamma interferon ELISPOT assay for quantitation of cellular immune responses to varicella-zoster virus. Clin Diagn Lab Immunol. 2001;8:871-879.
29. Mogg R, Fan F, Li X, et al. Statistical cross-validation of Merck's IFN-gamma ELIspot assay positivity criterion [abstract 495]. Presented at AIDS Vaccine 2003, September 18-21, 2003; New York, NY.
30. Alter G, Merchant A, Tsoukas CM, et al. Human immunodeficiency virus (HIV)-specific effector CD8 T cell activity in patients with primary HIV infection. J Infect Dis. 2002;185:755-765.
31. Slyker JA, Lohman BL, Mbori-Ngacha DA, et al. Modified vaccinia Ankara expressing HIVA antigen stimulates HIV-1-specific CD8 T cells in ELISpot assays of HIV-1 exposed infants. Vaccine. 2005;23:4711-4719.
32. Goonetilleke N, Moore S, Dally L, et al. Induction of multifunctional human immunodeficiency virus type 1 (HIV-1)-specific T cells capable of proliferation in healthy subjects by using a prime-boost regimen of DNA- and modified vaccinia virus Ankara-vectored vaccines expressing HIV-1 gag coupled to CD8(+) T-cell epitopes. J Virol. 2006;80:4717-4728.
33. Mulligan MJ, Russell ND, Celum C, et al. Excellent safety and tolerability of the human immunodeficiency virus type 1 pGA2/JS2 plasmid DNA priming vector vaccine in HIV type 1 uninfected adults. AIDS Res Hum Retroviruses. 2006;22:678-683.
34. Cox JH, Ferrari G, Kalams SA, et al. Results of an ELISPOT proficiency panel conducted in 11 laboratories participating in international human immunodeficiency virus type 1 vaccine trials. AIDS Res Hum Retroviruses. 2005;21:68-81.
35. Gupta SB, Mast CT, Wolfe ND, et al. Cross-clade reactivity of HIV-1-specific T-cell responses in HIV-1-infected individuals from Botswana and Cameroon. J Acquir Immune Defic Syndr. 2006;42:135-139.